Chris Markoch

Chris Markoch

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Buy Alibaba Stock While It’s Still at a Good Valuation

Alibaba stock is at an all-time high after a stellar earnings report. But if investors want to wait for the dip, they may be waiting a while.

3 Reasons You Should Still Keep an Eye on Inovio Pharmaceuticals

INO stock is dropping on news that its Covid-19 vaccine candidate is falling behind more established candidates. But science says there may still be a chance.

5 Airline Stocks Set to Survive the Pandemic

The bar for airline stocks has been lowered, and now survival is the name of the game. Here are five airlines that will make it through.

XpresSpa Still Presents More Questions Than Answers

XSPA stock is having a terrific year. Bullish investors believe it can turn into a viable resource for Covid-19 testing. That's a questionable assumption.

Workhorse Group Has Everything But Sales

For investors considering jumping on WKHS stock, the formula is simple. Turn the good intentions of its customers into sales.